Company: OSRH
Filing Date: 2025-04-22
Form Type: 10-K
Source: 0001213900-25-034116
Chunk: 76

Company: OSR Holdings, Inc.
Filing Date: 2025-04-22
Form: 10-K
Item: Item 1
Chunk 76
---
 or development-stage technologies
or programs, which introduces additional risks for our company. Identifying, selecting, and acquiring product candidates demands significant
technical, financial, and human resources expertise. These efforts may not lead to the acquisition or licensing of a viable product candidate,
potentially resulting in the diversion of our management’s time and the expenditure of resources without any resulting tangible
benefits. If we struggle to identify programs that eventually result in successful commercial products, we could spend substantial amounts
of our capital and resources on evaluating, acquiring, and developing products that ultimately do not generate returns on our investments.

40

We may not be successful in our efforts to build a robust pipeline
of product candidates with commercial value.

A key element of our strategy is to acquire companies, programs, product
candidates, technologies or intellectual property that we believe are novel, employ differentiated mechanisms of action, are more advanced
in development than competitors, or have a combination of these attributes. In addition, we plan to seek strategic alliances, create joint
ventures or collaborations, or enter into licensing arrangements with third parties. We face significant competition in these opportunities,
and the negotiation process is time-consuming and complex. We may not be successful in our efforts in building a robust pipeline
of product candidates through acquisitions, licensing or through internal development or in progressing these product candidates through
clinical development.

Although we analyze whether we can replicate scientific results observed
prior to our acquisition or investment in a product candidate, we may not be successful in doing so after our investment. Even if we are
successful in building our pipeline of product candidates, the potential product candidates that we identify may not be suitable for clinical
development or generate acceptable clinical data, including as a result of unacceptable toxicity or other characteristics that indicate
that they are unlikely to receive approval from the U.S. Food and Drug Administration (“FDA”) or other regulatory
authorities or achieve market acceptance. If we do not successfully develop and commercialize product candidates, we will not be able
to generate product revenue in the future, which likely would result in significant harm to our financial position and adversely affect
our stock price.

The market opportunities for our product candidates may vary
widely as we intend to develop product candidates to address unmet diseases, with some product candidates having smaller target markets,
and our estimates of the prevalence of our target patient populations may be inaccurate.

We have acquired, and seek to create or acquire, companies or select
intellectual property with the potential as breakthrough designations for unmet